ArticlePloS one2017
Novel and ultra-rare damaging variants in neuropeptide signaling are associated with disordered eating behaviors.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Integrative GWAS identifies novel loci and genetic links between psychiatric and metabolic factors in anorexia nervosa.Molecular psychiatry · 2026Pooled it
- Brain-based gene expression of putative risk genes for anorexia nervosa.Molecular psychiatry · 2023Pooled it
- Animal Models for Anorexia Nervosa-A Systematic Review.Frontiers in human neuroscience · 2020Pooled it
- Patients with anorexia nervosa have an increased burden of rare, damaging mutations in the BBOX1 gene.Journal of eating disorders · 2025Article
- Inclusion of the severe and enduring anorexia nervosa phenotype in genetics research: a scoping review.Journal of eating disorders · 2024Article
- The head mesodermal cell couples FMRFamide neuropeptide signaling with rhythmic muscle contraction in C. elegans.Nature communications · 2023Article
- Gene variants in eating disorders. Focus on anorexia nervosa, bulimia nervosa, and binge-eating disorder.Journal of preventive medicine and hygiene · 2022Review
- Genetics and neurobiology of eating disorders.Nature neuroscience · 2022Review
- Genetics of eating disorders in the genome-wide era.Psychological medicine · 2021Review
- Activation of ventral tegmental area neurotensin Receptor-1 neurons promotes weight loss.Neuropharmacology · 2021Article
- The Role of Central Neurotensin in Regulating Feeding and Body Weight.Endocrinology · 2021Review
- Estimating the Prevalence and Genetic Risk Mechanisms of ARFID in a Large Autism Cohort.Frontiers in psychiatry · 2021Article
- Article
- Molecular neuroanatomy of anorexia nervosa.Scientific reports · 2020Article
- Genetic contributions to the etiology of anorexia nervosa: New perspectives in molecular diagnosis and treatment.Molecular genetics & genomic medicine · 2020Review
- Exome sequencing in a familial form of anorexia nervosa supports multigenic etiology.Journal of neural transmission (Vienna, Austria : 1996) · 2019Article
- Article
- Determination of neurotensin projections to the ventral tegmental area in mice.Neuropeptides · 2018Article
- Role of central neurotensin in regulating feeding: Implications for the development and treatment of body weight disorders.Biochimica et biophysica acta. Molecular basis of disease · 2018Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveEating disorders develop through a combination of genetic vulnerability and environmental stress, however the genetic basis of this risk is unknown.
methodsTo understand the genetic basis of this risk, we performed whole exome sequencing on 93 unrelated individuals with eating disorders (38 restricted-eating and 55 binge-eating) to identify novel damaging variants. Candidate genes with an excessive burden of predicted damaging variants were then prioritized based upon an unbiased, data-driven bioinformatic analysis. One top candidate pathway was empirically tested for therapeutic potential in a mouse model of binge-like eating.
resultsAn excessive burden of novel damaging variants was identified in 186 genes in the restricted-eating group and 245 genes in the binge-eating group. This list is significantly enriched (OR = 4.6, p<0.0001) for genes involved in neuropeptide/neurotrophic pathways implicated in appetite regulation, including neurotensin-, glucagon-like peptide 1- and BDNF-signaling. Administration of the glucagon-like peptide 1 receptor agonist exendin-4 significantly reduced food intake in a mouse model of 'binge-like' eating.
conclusionsThese findings implicate ultra-rare and novel damaging variants in neuropeptide/neurotropic factor signaling pathways in the development of eating disorder behaviors and identify glucagon-like peptide 1-receptor agonists as a potential treatment for binge eating.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.